E2031
Eliprodil
≥98% (HPLC), powder
别名:
α-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol, SL 820715
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C20H23ClFNO
化学文摘社编号:
分子量:
347.85
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 5 mg/mL, clear, H2O: insoluble
originator
Sanofi Aventis
storage temp.
2-8°C
SMILES string
OC(CN1CCC(CC1)Cc2ccc(F)cc2)c3ccc(Cl)cc3
InChI
1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2
InChI key
GGUSQTSTQSHJAH-UHFFFAOYSA-N
Gene Information
human ... GRIN2B(2904)
rat ... Adra1a(29412)
Biochem/physiol Actions
NR2B selective NMDA glutamate receptor antagonist which appears to target the "polyamine site" on the NMDA receptor, setting it apart from other NR2B receptor antagonists. Possesses neuroprotective effects in models of ischemia, but prolongs the QT interval in patients; currently under investigation for acute and chronic pain.
NR2B selective NMDA glutamate receptor antagonist.
Features and Benefits
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves
法规信息
新产品
此项目有
A Y Bespalov et al.
European journal of pharmacology, 390(3), 303-311 (2000-03-10)
NMDA receptor antagonists have been reported to affect learned behaviors conditioned with abused drugs, with the outcome dependent, in part, on the class of NMDA receptor antagonist used. The present study tested the ability of various site-selective NMDA receptor antagonists
J D Thomas et al.
Psychopharmacology, 175(2), 189-195 (2004-04-06)
Prenatal exposure to alcohol can disrupt brain development, leading to a variety of behavioral alterations, including learning deficits. We have postulated that some central nervous system damage may be due to N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity that occurs during ethanol withdrawal.
Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.
J E Nash et al.
Experimental neurology, 155(1), 42-48 (1999-01-27)
Current symptomatic treatment for Parkinson's disease is based largely on dopamine-replacing agents. The fact that long-term treatment with these drugs is characterized by many side effects has lead to widespread interest in nondopaminergic therapies. To date, however, it has proved
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| E2031-50MG | 04061832090634 |
| E2031-10MG | 04061832090627 |